Quale sarebbe il prezzo per DelMar Pharmaceuticals, Inc. (DMPWW)

Il prezzo per DelMar Pharmaceuticals, Inc. (DMPWW) è $0.005

Qual è la capitalizzazione di mercato per DelMar Pharmaceuticals, Inc. (DMPWW)

La capitalizzazione di mercato per DelMar Pharmaceuticals, Inc. (DMPWW) è $1.74K

DelMar Pharmaceuticals, Inc. (DMPWW) Rapporto P/S

Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.

Anno	Rapporto P/S	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/S

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/S	Differenza del rapporto P/S	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	9.88	-	US
Argenx SE ARGX.US	10.30	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.98	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Azienda

Rapporto P/S

Differenza del rapporto P/S

Il paese